ArticleCombinatorial chemistry & high throughput screening2026
Evaluation of Cranberry as a Novel Therapeutic Strategy for Intracerebroventricular (ICV) Quinolinic Acid-induced Cognitive Impairment in Rats.
Article in Combinatorial chemistry & high throughput screening, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCranberry (Vaccinium macrocarpon) is rich in vitamins, minerals, anthocyanins, flavonoids, and phenolic acids, offering potent antioxidant activity. Polyphenols in cranberries are linked to neuroprotective effects via modulation of oxidative stress, inflammation, and signaling pathways.
objectivesThis study evaluated the neuroprotective effects of cranberries on behavioral and neurochemical abnormalities induced by intracerebroventricular (ICV) quinolinic acid (QA) in Wistar rats, focusing on ERK and PI3K/AKT pathway modulation.
methodsThirty Wistar rats were divided into groups: control, QA (240 nM, ICV), QA + cranberry (0.5 g/kg, p.o.), and QA + high-dose cranberry (2 g/kg, p.o.). Treatments continued for 21 days. Behavioral performance was assessed via Novel Object Recognition, Morris Water Maze, rotarod, and footprint analysis. Biochemical assays measured oxidative/nitrosative stress markers, mitochondrial complex activities, and cholinergic function. Histological analysis evaluated neuronal integrity.
resultsQA treatment impaired cognition, motor function, and mitochondrial activity, increased oxidative stress (↑MDA, ↑nitrite, ↓GSH), and induced cholinergic dysfunction. Cranberry supplementation, particularly at 2 g/kg, significantly improved memory, learning, and motor coordination, restored GSH, reduced MDA and nitrite levels, enhanced mitochondrial complexes I, II, and IV activities, and normalized cholinergic markers. Histology confirmed reduced neuronal degeneration and inflammation. DISCUSSION: Cranberries exhibit neuroprotective effects likely via antioxidant, antiinflammatory, and anti-excitotoxic mechanisms, promoting synaptic plasticity and neuronal survival.
conclusionCranberries may serve as a potential natural therapeutic strategy for cognitive deficits and neurodegenerative conditions, warranting further translational studies.
Indexed as
Identifiers
40442918What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.